Status:
UNKNOWN
HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy
Lead Sponsor:
University Hospital Erlangen
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This is a phase II trial looking at the feasibility of HistoScanning- based dose-painting image- guided interstitial brachytherapy in non- metastatic prostate cancer Endpoints: Primary endpoint Eval...
Detailed Description
Rationale: The study is designed as a prospective monocentric phase II trial. The choice of the therapeutic concept is governed by the risk group that the patient falls into. Risk groups are defined ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically proven prostate cancer
- All cT1-3 carcinomas independent of grading and PSA value
- Prostate volume\< 70cc
- No distant metastases
- Karnofsky \> 60
- Written informed consent from the patient regarding study participation
- Exclusion criteria:
- All patients who do not meet the inclusion criteria
- T4 carcinomas
- Proven metastases N+ and/or M1
- Epidural or general anaesthesia not possible
- Pathological clotting parameters
Exclusion
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01409876
Start Date
September 1 2011
End Date
September 1 2016
Last Update
August 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Therapy University Hospital
Erlangen, Germany, 91054